-+ 0.00%
-+ 0.00%
-+ 0.00%

INCYTE’S FIRST-IN-CLASS MUTCALR-TARGETED MONOCLONAL ANTIBODY, INCA033989, GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA

Reuters·12/07/2025 14:30:03

Please log in to view news